Technical Analysis for URGN - UroGen Pharma Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 14.21 | -2.20% | -0.32 |
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| 20 DMA Support | Bullish | -2.20% | |
| Crossed Above 20 DMA | Bullish | -1.11% | |
| Calm After Storm | Range Contraction | 3.50% | |
| 20 DMA Resistance | Bearish | -0.35% | |
| Calm After Storm | Range Contraction | -0.35% | |
| NR7 | Range Contraction | -0.35% | |
| Fell Below 20 DMA | Bearish | -0.21% |
| Alert | Time |
|---|---|
| Down 2 % | about 13 hours ago |
| Possible NR7 | about 14 hours ago |
| Possible Inside Day | about 14 hours ago |
| 60 Minute Opening Range Breakdown | about 16 hours ago |
| Fell Below 10 DMA | about 16 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/09/2024
UroGen Pharma Ltd. Description
UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunotherapy Surgery Chemotherapy Antineoplastic Drugs Carcinoma Bladder Cancer Platform Technologies Botulinum Toxin Oab Interstitial Cystitis Overactive Bladder Tlr7 Two Platform Technologies Urinary Bladder
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.13 |
| 52 Week Low | 8.69 |
| Average Volume | 362,988 |
| 200-Day Moving Average | 15.12 |
| 50-Day Moving Average | 15.98 |
| 20-Day Moving Average | 14.10 |
| 10-Day Moving Average | 14.33 |
| Average True Range | 0.98 |
| RSI (14) | 45.95 |
| ADX | 13.97 |
| +DI | 21.17 |
| -DI | 21.48 |
| Chandelier Exit (Long, 3 ATRs) | 15.31 |
| Chandelier Exit (Short, 3 ATRs) | 15.30 |
| Upper Bollinger Bands | 15.38 |
| Lower Bollinger Band | 12.82 |
| Percent B (%b) | 0.54 |
| BandWidth | 18.16 |
| MACD Line | -0.37 |
| MACD Signal Line | -0.51 |
| MACD Histogram | 0.1478 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.06 | ||||
| Resistance 3 (R3) | 15.15 | 14.95 | 14.92 | ||
| Resistance 2 (R2) | 14.95 | 14.74 | 14.91 | 14.87 | |
| Resistance 1 (R1) | 14.58 | 14.60 | 14.48 | 14.49 | 14.83 |
| Pivot Point | 14.39 | 14.39 | 14.34 | 14.34 | 14.39 |
| Support 1 (S1) | 14.01 | 14.17 | 13.92 | 13.93 | 13.59 |
| Support 2 (S2) | 13.82 | 14.03 | 13.77 | 13.55 | |
| Support 3 (S3) | 13.45 | 13.82 | 13.50 | ||
| Support 4 (S4) | 13.36 |
